While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this ...

After decades without much movement, a handful of new treatments for this rare autoimmune disease are now approved, and ...

A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study ...

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer drug Keytruda.